Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo/Targeted Therapy - Trial NCT05923268
Access comprehensive clinical trial information for NCT05923268 through Pure Global AI's free database. This phase not specified trial is sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences and is currently Enrolling by invitation. The study focuses on Breast Cancer Female. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tomsk National Research Medical Center of the Russian Academy of Sciences
Timeline & Enrollment
N/A
Jun 04, 2023
Jun 15, 2024
Primary Outcome
Gamma camera-based whole-body [99mTc]Tc-G3-(G3S)3C uptake value (%),SPECT-based [99mTc]Tc-G3-(G3S)3C uptake value in tumor lesions (counts) [99mTc]Tc-G3-(G3S)3C uptake coinciding with tumor lesions will be assessed using single-photon emission computed tomography and measured in counts,SPECT-based [99mTc]Tc-G3-(G3S)3C background uptake value (counts),Tumor-to-background ratio (SPECT)
Summary
The study should evaluate distribution of [99mTc]Tc-G3-(G3S)3C in patients with primary
 HER2-positive and HER2-negative breast cancer
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05923268
Non-Device Trial